Home › Funds › Pivotal bioVenture Partners Investment Advisor LLC › RXRX

Pivotal bioVenture Partners Investment Advisor LLC position in RXRX

RECURSION PHARMACEUTICALCLASS A · Health Care

Pivotal bioVenture Partners Investment Advisor LLC reported holding 595,518 shares of RXRX (RECURSION PHARMACEUTICALCLASS A) in its Q2 2026 13F filing — a position valued at US$2.2M, representing 0.71% of its reported portfolio and ranking #13 among its reported holdings. Pivotal bioVenture Partners Investment Advisor LLC has disclosed RXRX holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)595.52K sh
Reported value held$2.19M
Portfolio Weight0.71%
First reportedQ4 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Pivotal bioVenture Partners Investment Advisor LLC's RXRX position evolved

Pivotal bioVenture Partners Investment Advisor LLC first disclosed a stake in RXRX in Q4 2024 at 595,518 shares (US$4.0M). Across 7 filings, Pivotal bioVenture Partners Investment Advisor LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 595,518 shares valued at US$2.2M.

Quarter by quarter

QuarterSharesValueChange
Q4 2024 595.52K $4.03M New
Q1 2025 595.52K $3.15M Hold
Q2 2025 595.52K $3.01M Hold
Q3 2025 595.52K $2.91M Hold
Q4 2025 595.52K $2.44M Hold
Q1 2026 595.52K $1.83M Hold
Q2 2026 595.52K $2.19M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RXRX and 13F data

RXRX (RECURSION PHARMACEUTICALCLASS A) is a Health Care company. 29 other funds we track also report a position in RXRX — the largest reported positions include ARK Invest (US$151.7M), SOFTBANK GROUP CORP. (US$50.0M), MIC Capital Management UK LLP (US$35.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RXRX

All RXRX fund holders →

FAQ

How long has Pivotal bioVenture Partners Investment Advisor LLC held RXRX?

Pivotal bioVenture Partners Investment Advisor LLC has disclosed RXRX holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is Pivotal bioVenture Partners Investment Advisor LLC's current position in RXRX?

As of Q2 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 595.52K shares of RXRX (RECURSION PHARMACEUTICALCLASS A), valued at $2.19M, representing 0.71% of its reported portfolio and ranking #13.

Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling RXRX?

In the latest 13F filing (Q2 2026), Pivotal bioVenture Partners Investment Advisor LLC held unchanged its position in RXRX.

Which other funds hold RXRX?

Other major institutional holders of RXRX include ARK Invest, SOFTBANK GROUP CORP., MIC Capital Management UK LLP, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.